Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetravalent inactivated enterovirus vaccine
- Development stage
- Phase 3
- Lead developer
- Sinovac Biotech
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The tetravalent inactivated enterovirus vaccine is a multivalent, whole-virus, inactivated vaccine developed to prevent hand, foot and mouth disease (HFMD) caused by four major enteroviruses: Enterovirus 71 (EV71), Coxsackievirus A16 (CA16), Coxsackievirus A10 (CA10), and Coxsackievirus A6 (CA6). The mechanism of action involves the induction of neutralizing antibodies against these viruses, providing broad protection for children who are most at risk for HFMD. This approach addresses the challenge of low cross-immunogenicity among different causative viruses. The world's first such tetravalent candidate was developed by Sinovac Biotech and approved for clinical trials as of December 2024[2]. The primary indication is prevention of HFMD.
- Other names
- tetravalent inactivated enterovirus vaccine
02
Targets
Coxsackievirus A6 capsid proteinsEnterovirus A71 capsid proteinEnterovirus capsid proteinCoxsackievirus A10 capsid protein
Beyond the preview
Go deeper on Tetravalent inactivated enterovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetravalent inactivated enterovirus vaccine.